Clinical Trials

Carcinoma, Basal Cell

NCT00833417 2026-05-11

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

104 enrolled 13 charts

Carcinoma, Basal Cell, Neoplasms, Basal Cell

NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

DermatologicGastrointestinalGynecologic

19 enrolled 10 charts

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT02523014 2026-05-08

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

124 enrolled

Phase 2 Active not recruiting

Meningioma

NCT06357988 2026-05-06

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

34 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02667574 2026-04-22

VISMONEO

55 enrolled

Phase 1 Active not recruiting

Carcinoma, Basal Cell

NCT00878163 2026-04-13

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

55 enrolled

Phase 2 Active not recruiting

Pancreatic Neoplasms

NCT01267955 2026-04-13

Vismodegib in Treating Patients With Advanced Chondrosarcomas

45 enrolled 10 charts

Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

NCT05651828 2026-04-01

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

34 enrolled

Skin Neoplasms

NCT03297606 2026-03-27

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Recruiting

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

48 enrolled

Gynecologic

Platinum-Resistant Fallopian Tube Carcinoma

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Phase 2 Active not recruiting

Neoplasms, Unknown Primary

NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

660 enrolled

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

NCT05561634 2025-09-30

RADIOSONIC

82 enrolled

Carcinoma, Basal Cell

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT05463757 2025-04-04

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

Recruiting

80 enrolled

Basal Cell Nevus Syndrome, Carcinoma, Carcinoma, Basal Cell, Skin Neoplasms, Neoplasms, Basal Cell

NCT01064622 2024-11-19

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

118 enrolled 14 charts

Pancreatic Neoplasms

NCT06344052 2024-09-20

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

80 enrolled

Carcinoma, Basal Cell

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Phase EARLY_PHASE1 Withdrawn

Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02073838 2023-09-29

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

Other hematologic neoplasm

23 enrolled

Leukemia, Myeloid, Acute

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

228 enrolled

Glioblastoma

NCT03035188 2022-02-11

NICCI

40 enrolled

Carcinoma, Basal Cell

NCT02436408 2021-10-28

VISORB

Phase 4 Completed

35 enrolled 9 charts

Carcinoma, Basal Cell

NCT03052478 2021-06-08

Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

10 enrolled

Stomach Neoplasms

NCT01835626 2021-05-03

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

24 enrolled 16 charts

DermatologicHead & Neck

Head and Neck Neoplasms, Skin Neoplasms

NCT02366312 2021-02-18

KCOT

2 enrolled 8 charts

Odontogenic Cysts

NCT00957229 2021-01-11

GDC-0449

41 enrolled 10 charts

Basal Cell Nevus Syndrome

NCT00887159 2021-01-05

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

168 enrolled 11 charts

Thoracic

Small Cell Lung Carcinoma

NCT01556009 2020-11-02

Vismodegib

24 enrolled

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02371967 2020-10-09

ROSETT

Completed

50 enrolled

Carcinoma, Basal Cell

NCT02956889 2020-01-29

virgilio

Phase 2 Terminated

14 enrolled

Carcinoma, Basal Cell

NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Phase 2 Withdrawn

Basal Cell Nevus Syndrome

NCT02067104 2019-08-14

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

Phase 2 Terminated

9 enrolled 4 charts

Carcinoma, Basal Cell

NCT01367665 2019-06-06

STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

1,232 enrolled 19 charts

Carcinoma, Basal Cell

NCT01700049 2019-05-23

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

28 enrolled 9 charts

Carcinoma, Basal Cell

NCT01601184 2019-05-21

Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway

Phase 1/2 Terminated

24 enrolled

Microphthalmia, Isolated, with Coloboma 5, Medulloblastoma

NCT02674009 2019-05-13

NIELS

Completed

67 enrolled

Carcinoma, Basal Cell

NCT01088815 2019-04-26

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

98 enrolled 14 charts

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

NCT01537107 2019-04-08

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Phase 1 Completed

31 enrolled

Pancreatic Neoplasms

NCT02690948 2019-03-08

Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

Phase 1/2 Completed

16 enrolled 15 charts